## COO: The Cooper Companies, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.87 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-7.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($72.00)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. The Cooper Companies Experiences Revision in Stock Evaluation Amid Market Dynamics**
- Source: Markets Mojo | 20251201T160200 | Neutral | Relevance: 99%
- The Cooper Companies, Inc. has undergone a stock evaluation revision due to market fluctuations, with its stock currently at $77.93. The company has experienced significant volatility over the past year, with a high of $106.63 and a low of $61.77. Technical indicators suggest mixed signals, including a mildly bullish sentiment from MACD and KST, while its year-to-date performance lags behind the S&P 500, highlighting ongoing challenges.

**2. Curious about The Cooper Companies (COO) Q4 Performance? Explore Wall Street Estimates for Key Metrics**
- Source: Nasdaq | 20251201T141500 | Neutral | Relevance: 98%
- The Cooper Companies (COO) is projected to report Q4 earnings of $1.11 per share and revenues of $1.06 billion, indicating year-over-year increases. Analysts have revised the EPS estimate downwards by 0.4% in the last 30 days. The article details specific revenue estimates by category and geography, highlighting varied growth expectations across its business segments and regions.

**3. Curious about The Cooper Companies (COO) Q4 Performance? Explore Wall Street Estimates for Key Metrics**
- Source: Yahoo Finance | 20251201T141500 | Neutral | Relevance: 98%
- The Cooper Companies (COO) is expected to report Q4 earnings of $1.11 per share, a 6.7% increase year-over-year, with revenues forecasted at $1.06 billion, up 4.1%. Analyst estimates for key metrics, including revenue by category and geography, provide deeper insights into potential performance. Despite these projections, COO currently holds a Zacks Rank #4 (Sell), suggesting a near-term underperformance relative to the market.

**4. Activist Push for Vision Care Focus Could Be a Game Changer for Cooper Companies (COO)**
- Source: Simply Wall Street | 20251201T030721 | Somewhat-Bullish | Relevance: 98%
- Activist investor Browning West LP has urged Cooper Companies (COO) to consider spinning off its CooperSurgical business and focus solely on vision care due to underperformance and structural concerns. This push for a pure-play vision care business aligns with similar calls from Jana Partners LLC, highlighting a potential shift in the company's investment narrative. While the immediate revenue driver is the MyDAY product line, the evolving board dynamics and competitive pricing pressures in Asia Pacific are key factors for investors to monitor.

**5. Calvert VP SRI Mid Cap Portfolio's The Cooper Companies Inc(COO) Holding History**
- Source: GuruFocus | 20251130T035048 | Neutral | Relevance: 98%
- This article provides a historical overview of Calvert VP SRI Mid Cap Portfolio's holdings in The Cooper Companies Inc (COO). It details quarterly buy and sell activities, average prices, and estimated gains for the portfolio's COO shares. Additionally, it lists recent news articles related to The Cooper Companies, including boardroom pushes and analyst downgrades.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 10, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Citigroup | $88 | $72 | +22% |
| 2025-12-08 | Morgan Stanley | $83 | $76 | +9% |
| 2025-12-08 | Goldman Sachs | $71 | $64 | +11% |
| 2025-12-05 | Stifel | $95 | $85 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Citigroup | main | Neutral |
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Goldman Sachs | main | Sell |
| 2025-12-05 | Stifel | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.14M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-1.1%)
- Blackrock Inc.: 7.7% (-0.8%)
- Capital World Invest: 5.3% (+25.7%)
- T. Rowe Price Invest: 4.9% (+33.2%)
- State Street Corpora: 4.3% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 10 raises (avg +14%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.87 indicates undervaluation relative to growth. Analyst sentiment positive (10 raises, avg +14%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.1B |
| Beta | 1.05 |
| 52W Range | $61.78 - $100.47 |
| Short Interest | 3.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.87 |
| Forward P/E | 15.4 |
| Current P/E | 16.8 |
| YoY Growth | 9.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 9.5% to 2.0% (-7.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.0pp (needs >4.0% for momentum thesis). MRS_5 (-2.8%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.8% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.99% (CS: 78) | Neutral |
| RSI_14 | 59.4 | Neutral |
| MACD Histogram | 0.46 | Bullish |
| vs SMA20 | 1.038x | Above |
| vs SMA50 | 1.061x | Above |
| vs SMA200 | 1.011x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $75.84
- **Stop Loss:** $72.00 (5.1% risk)
- **Target:** $83.52 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 260
- **Position Value:** $19,718.40
- **Portfolio %:** 19.72%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-03-05 (Est: $1.03)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.11 | $1.15 | +3.3% |
| 2025Q3 | $1.07 | $1.10 | +3.0% |
| 2025Q2 | $0.93 | $0.96 | +3.3% |
| 2025Q1 | $0.91 | $0.92 | +0.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*